Figure 8

ddPCR results on a cohort of commercial clinical ER +ve breast cancer patients. (a) Results from screening 96 ctDNA samples for PIK3CA and ESR1 mutation. Samples found to be positive for PIK3CA mutation were tested for the presence of an ESR1 mutation (Y537C/N/S and D538G). (b) Commercial clinical PIK3CA mutant positive sample positive for E542K, H1047R and H1047L mutations and borderline for E542K (sample 96).